Hetta Helal F, Zahran Asmaa M, El-Mahdy Reham I, Nabil Emad Eldin, Esmaeel Hend M, Elkady Ola A, Elkady Azza, Mohareb Dina A, Mahmoud Mostafa Mohammed, John James
Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Email:
Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1927-1933. doi: 10.31557/APJCP.2019.20.6.1927.
Background: Lung cancer is one of the main human health threats. Survival of lung cancer patients depends on the timely detection and diagnosis. Among the genetic irregularities that control cancer development and progression, there are microRNAs (miRNAs). This study aimed to assess the plasma level of circulating miRNA-17 and miRNA-222 as non-invasive markers in non-small-cell lung cancer (NSCLC) patients. Patients and methods: A total of 40 patients with NSCLC and 20 healthy controls who were matched in terms of age and sex with the patient group were included in this case-control study.. Estimation of miRNA-17 and miRNA-222 expression profiles in the plasma was done using quantitative real-time PCR (qRT-PCR). The relationship between both markers and their clinicopathological features were also determined. Receiver operating characteristic (ROC) curve analysis was done to evaluate the role of these microRNAs in NSCLC diagnosis and follow-up. Results: MiRNA-17 and miRNA-222 levels were significantly upregulated in NSCLC patients compared with controls (48.32±12.35 vs 1.16±0.19 and 34.53±3.1 vs 1.22±0.14) (P=0.000). Plasma miRNA-17 level was increased, and the miRNA-222 level was decreased across different stages of the disease; however, these differences d were not statistically significant (P=0.4, P=0.5, respectively). The miRNA-17 levels were higher in the lung cancer patients with metastasis , but miRNA-222 levels were lower patients without metastasis. We found no statistically significant difference in this regard(P=0.4 vs P=0.3, respectively). ROC curve analysis showed that the sensi¬tivity and specificity of miRNA-17 were 77.78% and 87.50% , and of miRNA-222 were 50% and 88.89%. Conclusion: MiRNA-17 and miRNA-222 can be considered as non-invasive biomarkers for detection of early lung carcinogenesis and metastasis in patients with NSCLC, hence providing a basis for the development of novel therapeutic approaches.
肺癌是对人类健康的主要威胁之一。肺癌患者的生存取决于及时的检测和诊断。在控制癌症发展和进展的基因异常中，存在微小RNA（miRNA）。本研究旨在评估循环miRNA-17和miRNA-222的血浆水平作为非小细胞肺癌（NSCLC）患者的非侵入性标志物。
本病例对照研究共纳入40例NSCLC患者和20名年龄和性别与患者组匹配的健康对照。使用定量实时PCR（qRT-PCR）对血浆中miRNA-17和miRNA-222的表达谱进行评估。还确定了这两种标志物与其临床病理特征之间的关系。进行受试者操作特征（ROC）曲线分析以评估这些微小RNA在NSCLC诊断和随访中的作用。
与对照组相比，NSCLC患者中miRNA-17和miRNA-222水平显著上调（48.32±12.35对1.16±0.19以及34.53±3.1对1.22±0.14）（P = 0.000）。在疾病的不同阶段，血浆miRNA-17水平升高，而miRNA-222水平降低；然而，这些差异无统计学意义（分别为P = 0.4，P = 0.5）。有转移的肺癌患者中miRNA-17水平较高，但无转移患者中miRNA-222水平较低。我们发现在这方面无统计学显著差异（分别为P = 0.4对P = 0.3）。ROC曲线分析表明，miRNA-17的敏感性和特异性分别为77.78%和87.50%，miRNA-222的敏感性和特异性分别为50%和88.89%。
MiRNA-17和miRNA-222可被视为检测NSCLC患者早期肺癌发生和转移的非侵入性生物标志物，从而为开发新的治疗方法提供依据。
